Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesInsulin Secretion and Insulin Sensitivity in Relation to Fasting Glucose in Healthy Subjects
Diabetes Care, 03/05/07
Bo Ahrén, MD, PHD., - Does high, but still normal, fasting glucose contribute to augmented insulin secretion?
>Summary: A total of 148 healthy 50+ year old women underwent a glucose-dependent arginine stimulation test and a 2-h euglycemic-hyperinsulinemic clamp. In the arginine test, arginine (5 g) was injected intravenously under baseline (fasting) conditions and after raising the glucose levels to 15 and >28 mmol/l. From this test, the acute insulin response (AIR) to arginine during the three glucose levels (AIR1, AIR2, and AIR3) were estimated.
Outcomes: The researchers concluded that 1) raised fasting glucose augments baseline and maximal arginine-induced insulin secretion in healthy subjects, and 2) this is associated with reduced insulin sensitivity. This suggests that high, but still normal, fasting glucose may contribute to the augmented insulin secretion in subjects with low insulin sensitivity
| Previous Article | Next Article |
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Vascular Health and Risk Management, 05/11/09
A randomized trial of therapies for type 2 diabetes and coronary artery disease
New England Journal of Medicine, 06/10/09
Sponsor
Article Search
Sponsor